2026-10-28 16:50:54 UTC#530995newconfirmednews
Dr. Reddy's Srikakulam unit receives VAI classification from U.S. FDA, inspection closed
zerodha pulseimportance 0.40trust 0.70Dr. Reddy's Laboratories Ltd. +0.40U.S. Food and Drug Administration +0.40
RDY stock news
RDY stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-10-26 11:00:17 UTC#514318duplicateconfirmednews
Indian markets snap four-day losing streak; Dr. Reddy's, JSW Steel, Shriram Finance, Tata Consumer lead gains
zerodha pulseimportance 0.30trust 0.60Dr. Reddy's Laboratories Ltd. +0.40JSW Steel Ltd. +0.40Shriram Finance Ltd. +0.40+2 entities
2026-10-26 10:20:43 UTC#513826duplicateconfirmednews
Indian shares rebound as earnings gains offset crude oil inflation concerns
reutersimportance 0.30trust 0.90Dr. Reddy's Laboratories Ltd. +0.40JSW Steel Ltd. +0.40Kotak Mahindra Bank Ltd. +0.40+2 entities
2026-10-24 04:20:00 UTC#509662newconfirmednews
Dr. Reddy's Laboratories average analyst price target cut to $13.12, implies 1% downside
tradingviewimportance 0.30trust 0.80Dr. Reddy's Laboratories Ltd. -0.10FactSet Research Systems Inc. 0
2026-10-24 03:53:30 UTC#509678duplicateconfirmednews
Dr. Reddy's Labs reports 36% Q2 profit decline, supports new trade margin regulations
2026-10-23 23:10:30 UTC#509418updateconfirmednews
Dr. Reddy's confirms semaglutide relaunch for November 2026, maintains 6M-7M device production target
2026-10-23 19:21:28 UTC#508615duplicateconfirmeddata release
Dr. Reddy's Laboratories reports Q2 GAAP EPS of $0.17 and revenue of $1.75B
2026-10-23 17:10:45 UTC#508129duplicateconfirmednews
Dr. Reddy's Q2 revenue down 1.5% on lenalidomide decline; semaglutide relaunch set for November
quartrimportance 0.30trust 0.60Dr. Reddy's Laboratories Ltd. +0.20Lenalidomide -0.40Semaglutide +0.30
2026-10-23 16:29:36 UTC#508000duplicateconfirmednews
Dr. Reddy's Laboratories Q2 net profit falls 32% to ₹913 crore on lower revenue
2026-10-23 13:57:03 UTC#507084newconfirmednews
Dr. Reddy's Laboratories Q2 2027 earnings call commences
2026-10-23 13:32:47 UTC#507024duplicateconfirmednews
Dr. Reddy's Laboratories Q2 FY27 net profit falls 36% YoY to Rs 913 crore on revenue decline
2026-10-23 12:48:16 UTC#506665duplicateconfirmednews
Dr. Reddy's Q2 FY27 Revenue ₹8,671 Cr, EBITDA Margin 20.6% Amid Lenalidomide Headwinds
2026-10-23 12:29:33 UTC#506587duplicateconfirmednews
Dr. Reddy's Laboratories reports Q2 profit of 9.25 billion rupees, beating analyst estimates
reutersimportance 0.30trust 0.90Dr. Reddy's Laboratories Ltd. +0.30Semaglutide -0.40India +0.20+2 entities
2026-10-23 12:08:19 UTC#506469duplicateconfirmednews
Dr. Reddy's Laboratories reports quarterly profit exceeding analyst estimates
2026-10-23 10:35:59 UTC#505810duplicateconfirmednews
Dr. Reddy's launches Obeda Pro and Obeda Plus in India following Obeda supply recall
2026-10-23 10:00:00 UTC#505579newconfirmednews
Upcoming US Corporate Earnings Calendar for the Week of October 26, 2026
dow_jonesimportance 0.30trust 0.90American Express Company 0Autoliv, Inc. 0Booz Allen Hamilton Holding Corporation 0+2 entities
2026-10-23 09:39:11 UTC#505524updateconfirmednews
Dr. Reddy's launches new generic Ozempic brands following Obeda supply disruption
2026-10-23 09:34:32 UTC#505508newreportednews
Dr. Reddy's launches Obeda Pro and Obeda Plus in India following recall of original Obeda injection, Reuters reports
2026-10-21 09:27:21 UTC#491848updateconfirmednews
Dr. Reddy's receives DCGI approval for toripalimab as first-line treatment for ESCC in India
zerodha pulseimportance 0.40trust 0.70Dr. Reddy's Laboratories Ltd. +0.40Drugs Controller General of India +0.20Toripalimab +0.40+1 entities
2026-10-21 07:03:14 UTC#491339newconfirmednews
Dr. Reddy’s receives DCGI approval for Zytorvi to treat esophageal cancer in India
zerodha pulseimportance 0.40trust 0.70Dr. Reddy's Laboratories Ltd. +0.50Shanghai Junshi Biosciences Co., Ltd. +0.50Zytorvi +0.50+1 entities